Skip to main content

Short Reads: Feb 1, 2002 (rev. 1)


Whatever happened to the good old microarray? Genicon Sciences and BD Biosciences Clontech have teamed up to build “next-generation” microarrays using resonance light scattering technology. Meanwhile, EraGen Biosciences and McGill University will work on designing universal DNA microarrays.


Human Genome Sciences scratched money together to finance three new building projects: a large-scale manufacturing plant, a corporate and R&D campus, and a research center. All of these will be built less than a mile from HGS’ existing campus in Rockville, Md.


The HGBASE polymorphism database was renamed HGVbase because of its new additional role as database for mutations collected from the Human Genome Variation Society. The depository remains fully academic.


Gearing up for CASP5, the Pittsburgh Supercomputing Center and Compaq have agreed to provide the compute power to support the biannual protein-structure determination competition. (Oh, right, it’s not a competition. We forgot.)


Celera Genomics and Syrrx formed a structural proteomics alliance to speed up the discovery of small-molecule drugs. Syrrx will use its technology to figure out the structures of proteins identified by Celera.

San Diego-based Illumina has nearly tripled the capacity of its oligo-manufacturing facility. President and CEO Jay Flatley says this should bring the oligo cost down to 18 cents per base by the first quarter of this year.


Belgian companies Galapagos Genomics, in functional genomics, and Euroscreen, in G-protein coupled receptors, will work together to identify ligands of orphan GPCRs.


Hey, look, it’s a Kodak moment. Eastman Kodak’s scientific imaging division made a deal to market and distribute 20/20 GeneSystems’ tool for multiplex protein analysis.

Lynx and the Dana-Farber Cancer Institute have formed a research collaboration using Lynx’s sequencing technology to study AIDS cellular targets.


In conjunction with researchers at the University of Washington and DuPont, Silicon Valley’s SRI International took on the newly sequenced Agrobacterium tumefaciens, studying it to come up with a database of its genome and a computational analysis of its metabolic pathways.


GenoSpectra, a genomics and proteomics company using fiber-optic technology and based in Fremont, Calif., announced the completion of a $20 million private placement, including funding from founding investor Alejandro Zaffaroni.


The money’s rolling in for Avalon Pharmaceuticals as well. The company raised $70 million, which will allow for the addition of a new genomics-based discovery system.


We’ve been hearing about problems with the disbursement of French genomics funding, but Genome Express seemingly hasn’t had any trouble. The sequencing-based company closed a second round of financing worth about $11 million.


Gene Logic signed a database agreement with Aventis Pharmaceuticals, which will provide samples that Gene Logic will use to generate data.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.